Rapamycin extends murine lifespan but has limited effects on aging

Aging is a major risk factor for a large number of disorders and functional impairments. Therapeutic targeting of the aging process may therefore represent an innovative strategy in the quest for novel and broadly effective treatments against age-related diseases. The recent report of lifespan extension in mice treated with the FDA-approved mTOR inhibitor rapamycin represented the first demonstration of pharmacological extension of maximal lifespan in mammals.

Read the full abstract on PubMed →

Neff, F., et al. (2013). Rapamycin extends murine lifespan but has limited effects on aging. The Journal of clinical investigation. https://doi.org/10.1172/JCI67674

@article{NEF2013,
  author       = {Neff, F. and Ehninger, D. and others},
  title        = {{Rapamycin extends murine lifespan but has limited effects on aging}},
  journal      = {The Journal of clinical investigation},
  year         = {2013},
  doi          = {10.1172/JCI67674},
  note         = {PMID: 23863708},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record NEF2013) [Data set]. https://mtor-atlas.org/study/NEF2013/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_NEF2013,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record NEF2013},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/NEF2013/},
  doi          = {10.5281/zenodo.22059963}
}